GMED GLOBUS MEDICAL INC
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 1237831 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.4%
TTM net income YoY31.6%
TTM EPS YoY31.4%
Revenue 3-yr CAGR36.8%
Net income 3-yr CAGR52.3%
Margins
Gross margin69.1%
Operating margin21.6%
Net margin17.8%
FCF margin24.4%
EBITDA margin28.7%
Returns
ROE12.1%
ROA10.5%
ROIC (approx.)12.9%
Asset turnover0.59x
Leverage & solvency
Liabilities / assets13.2%
Debt / equity0.00x
Current ratio4.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.66x
Accruals ratio-6.9%
Payout ratio—
Capex / revenue5.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.94B | $2.52B | $1.57B | $1.02B | $958.10M |
| Cost of revenue | $957.80M | $1.04B | $548.17M | $263.73M | $239.22M |
| Gross profit | $1.98B | $1.48B | $1.02B | $759.12M | $718.88M |
| R&D expense | $147.25M | $163.75M | $124.01M | $73.02M | $97.35M |
| SG&A expense | $1.18B | $981.36M | $643.84M | $432.12M | $408.15M |
| Operating income | $479.82M | $165.99M | $133.14M | $227.95M | $171.95M |
| Pretax income | $605.07M | $120.72M | $165.39M | $243.02M | $180.41M |
| Income tax | $67.20M | $17.74M | $42.52M | $52.85M | $31.22M |
| Net income | $537.87M | $102.98M | $122.87M | $190.17M | $149.19M |
| EBITDA | $756.66M | $419.38M | $278.67M | $296.20M | $241.82M |
| EPS (basic) | 3.98 | 0.76 | 1.09 | 1.89 | 1.48 |
| EPS (diluted) | 3.92 | 0.75 | 1.07 | 1.85 | 1.44 |
| Weighted avg. shares (diluted) | 137.06M | 137.86M | 114.63M | 102.64M | 103.62M |
| Banking | |||||
| Net interest income | — | -$4.19M | $20.13M | $14.23M | $9.30M |
| Balance sheet | |||||
| Cash & equivalents | $526.16M | $784.44M | $467.29M | $150.47M | $193.07M |
| Short-term investments | $31.09M | $105.62M | $50.50M | $295.59M | $250.38M |
| Receivables | $678.94M | $557.70M | $503.24M | $213.25M | $164.44M |
| Inventory | $759.28M | $659.23M | $848.13M | $298.98M | $237.00M |
| Current assets | $2.13B | $2.18B | $1.92B | $983.34M | $864.52M |
| PP&E, net | $564.45M | $561.91M | $586.93M | $243.73M | $221.08M |
| Goodwill | $1.44B | $1.43B | $1.43B | $197.47M | $179.71M |
| Intangibles | $745.06M | $795.12M | $924.60M | $63.57M | $68.66M |
| Total assets | $5.30B | $5.25B | $5.09B | $2.08B | $1.96B |
| Current liabilities | $498.50M | $855.91M | $392.35M | $159.20M | $140.16M |
| Total liabilities | $729.51M | $1.07B | $1.09B | $229.75M | $215.88M |
| Shareholders' equity | $4.57B | $4.18B | $4.00B | $1.85B | $1.74B |
| Cash flow statement | |||||
| Operating cash flow | $753.45M | $520.64M | $243.50M | $178.47M | $276.27M |
| Capital expenditure | $164.68M | $115.43M | $78.27M | $74.05M | $56.90M |
| Free cash flow | $588.77M | $405.21M | $165.22M | $104.42M | $219.38M |
| Investing cash flow | -$355.01M | -$176.05M | $302.97M | -$110.36M | -$375.94M |
| Financing cash flow | -$679.16M | -$27.70M | -$231.82M | -$109.96M | $54.15M |
| Depreciation & amortization | $276.84M | $253.39M | $145.53M | $68.25M | $69.87M |
| Stock-based compensation | $49.78M | $54.19M | $52.74M | $32.81M | $30.59M |
| Share buybacks | $300.45M | $85.79M | $225.56M | $144.49M | — |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.